High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Clarke, Alan T ^a   Johnson, Paul C D ^b,e   Hall, Gillian C ^c   Ford, Ian ^b   Mills, Peter R ^d  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Grimsdyke House London ^*  (United Kingdom)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SMOKING; UNITED KINGDOM; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; LIVER; MIDDLE AGED; RISK FACTOR;

AGED; ATORVASTATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; UNITED KINGDOM;

EID: 84978110444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151587     Document Type: Article

References (44)

1. Rabar S, Harker M, O'Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Brit Med J. 2014; 349:g4356 doi: 10.1136/bmj.g4356 PMID: 25035388
2. Goldacre B, Smeeth L. Mass treatment with statins. Brit Med J. 2014; 349:g4745 doi: 10.1136/bmj.g4745 PMID: 25056140
3. Godlee F. Statins and the BMJ. Brit Med J. 2014; 349:g5038 doi: 10.1136/bmj.g5038 PMID: 25103228
4. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. Brit Med J. 2014; 349:g3743 doi: 10.1136/bmj.g3743 PMID: 25035309
5. Clarke AT, Mills PR. Atorvastatin associated liver disease. Digest Liver Dis. 2006; 38:772-7
6. Perger L, Kohler M, Fattinger K, Flury R, Meier P, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003; 39:1096-7
7. Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med. 2002; 113:348-9 PMID: 12361829
8. Ridruejo E, Mando O. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol. 2002; 37:165-6 PMID: 12076881
9. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999; 353:1763-4
10. Jiménez-Alonso J, Osorio JM, Gutiérrez-Cabello F, LDe La Osa A, León L, MGarcía JD. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med. 1999; 159:1811-2
11. Geoghegan M, Smith V, Green JRB. Acute cholestatic hepatitis associated with atorvastatin. Gut. 2004; 53(Suppl. III):A123
12. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009; 29:412-422 doi: 10.1055/s-0029-1240010 PMID: 19826975
13. LaRosa John C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-1435 PMID: 15755765
14. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437-2445. PMID: 16287954
15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-1504. PMID: 15007110
16. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307-1316. PMID: 15337732
17. Gershovich OE, Lyman AE. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy. 2004; 24(1):150-4 PMID: 14740794
18. De Castro ML, Baz A, De Luaces C, Perez R et al. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol. 2006; 29(1):21-4 PMID: 16393626
19. Van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005; 42(5):402-4
20. Lata S, Chudy B. Cholestatic hepatitis caused by simvastatin in a 67 year old patient. Przegl Lek. 2006; 63(7):97-8
21. Currascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol. 2015. 62 (3):751-2 doi: 10.1016/j.jhep.2014.11.019 PMID: 25463547
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7 PMID: 7566020
23. Russo MW, Galanko JA, Shrestha R., Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplant. 2004; 10:1018-1023
24. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012; 56:374-380. doi: 10.1016/j.jhep.2011.07.023 PMID: 21889469
25. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005; 42:481-489 PMID: 16025496
26. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129:512-521 PMID: 16083708
27. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135:1924-1934 doi: 10.1053/j.gastro.2008.09.011 PMID: 18955056
28. Jones P et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia [The CURVES Study]. Am J Cardiol. 1998; 81:582-587 PMID: 9514454
29. Nawrocki JW. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995; 15: 678-682. PMID: 7749881
30. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. Brit Med J. 1999; 319;1492 PMID: 10582940
31. R Development Core Team. R: A language and environment for statistical computing. 2011. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/
32. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA et al. Expanded Clinical Evaluation of Lovastatin [EXCEL] study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991; 151:43-9 PMID: 1985608
33. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet. 1994; 344:1383-1389 PMID: 7968073
34. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285:1711-8 PMID: 11277825
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7 PMID: 7566020
36. Reuben A., Koch DG, Lee WM. Drug-induced acute liver failure: Results of a US multicenter, prospective study. Hepatology. 2010; 52:2065-2076 doi: 10.1002/hep.23937 PMID: 20949552
37. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003; 12:409-412 PMID: 12765306
38. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003; 15:921-924 PMID: 12867804
39. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007; 21:17-24 PMID: 17207162
40. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005; 17:589-590 PMID: 15827453
41. Czaja AJ. Drug-induced autoimmune-like hepatitis. Digest Dis Sci 2011; 56: 958-976 doi: 10.1007/s10620-011-1611-4 PMID: 21327704
42. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006; 40:757-61 PMID: 16940892
43. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol.2006; 97:61-67. PMID: 16377285
44. Bays H, Cohen D, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology 2014; 8:S47-S57 doi: 10.1016/j.jacl.2014.02.011 PMID: 24793441